Suppr超能文献

埃索美拉唑镁缓释胶囊鼻胃管给药性能的体外评价

In Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules.

作者信息

Hoover Alicia, Sun Dajun, Wen Hong, Jiang Wenlei, Cui Minglei, Jiang Xiaojian, Keire David, Guo Changning

机构信息

Division of Pharmaceutical Analysis, Food and Drug Administration, 645 S Newstead Avenue, Saint Louis, Missouri 63110.

Office of Generic Drugs, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993.

出版信息

J Pharm Sci. 2017 Jul;106(7):1859-1864. doi: 10.1016/j.xphs.2017.04.008. Epub 2017 Apr 15.

Abstract

Enteral feeding tubes are used to deliver food or drugs to patients who cannot swallow. To deliver delayed-release drugs that are formulated as enteric coated granules to these patients via feeding tubes requires that they be suspended in water before administration. Importantly, the suspension of enteric granules in water of varying pH can cause damage to the enteric coating and affect the bioavailability of the drug. Here, analytical methods for testing acid resistance stability and particle size distribution (PSD) of esomeprazole granules were used to monitor the integrity of the granule enteric coating after water pretreatment and delivery through an oral syringe and nasogastric (NG) tube. Granules from esomeprazole magnesium delayed-release capsules were transferred to an oral syringe, suspended in water, and delivered on the bench through an NG tube. Subsequently, acid resistance stability (i.e., the amount of drug released after 2-h acid dissolution) was determined via high-performance liquid chromatography, and the PSD were measured with a laser diffraction system. All the granules demonstrated acid resistance stability when the granules were delivered immediately (0 min incubation) through the oral syringe and NG tube. In contrast, some granules demonstrated significant drug release during acid exposure after a 15-min incubation period which mimics a possible delay in delivery of the drug from the syringe by the caregiver. A bimodal PSD was observed with these granules, which was attributed to debris from damaged enteric coating and particle agglomeration. The methods developed in this study could be used to distinguish batches with suboptimal product quality for delivery using NG tubes and to confirm the substitutability of generic drug products for this alternative route of administration.

摘要

肠内喂食管用于向无法吞咽的患者输送食物或药物。要通过喂食管向这些患者输送制成肠溶包衣颗粒的缓释药物,需要在给药前将其悬浮于水中。重要的是,肠溶颗粒在不同pH值的水中悬浮会破坏肠溶包衣并影响药物的生物利用度。在此,采用分析方法检测埃索美拉唑颗粒的耐酸稳定性和粒度分布(PSD),以监测水预处理后及通过口服注射器和鼻胃管给药后颗粒肠溶包衣的完整性。将埃索美拉唑镁缓释胶囊中的颗粒转移至口服注射器中,悬浮于水中,并在实验台上通过鼻胃管给药。随后,通过高效液相色谱法测定耐酸稳定性(即2小时酸溶后释放的药物量),并用激光衍射系统测量PSD。当颗粒通过口服注射器和鼻胃管立即给药(孵育0分钟)时,所有颗粒均表现出耐酸稳定性。相比之下,在模拟护理人员从注射器给药可能延迟的15分钟孵育期后,一些颗粒在酸暴露期间表现出显著的药物释放。观察到这些颗粒具有双峰PSD,这归因于受损肠溶包衣的碎片和颗粒团聚。本研究中开发的方法可用于区分使用鼻胃管给药时产品质量欠佳的批次,并确认仿制药产品用于这种替代给药途径的可替代性。

相似文献

1
In Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules.
J Pharm Sci. 2017 Jul;106(7):1859-1864. doi: 10.1016/j.xphs.2017.04.008. Epub 2017 Apr 15.
8
Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing.
Aliment Pharmacol Ther. 2003 Sep 15;18(6):581-6. doi: 10.1046/j.1365-2036.2003.01667.x.
9
Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.
Dig Dis Sci. 1996 Mar;41(3):475-9. doi: 10.1007/BF02282321.
10
Accuracy of hydrocortisone dose administration via nasogastric tube.
Clin Endocrinol (Oxf). 2019 Jan;90(1):66-73. doi: 10.1111/cen.13876. Epub 2018 Nov 9.

本文引用的文献

1
Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
Drug Dev Ind Pharm. 2010 Feb;36(2):180-9. doi: 10.3109/03639040903468811.
3
Medication administration through enteral feeding tubes.
Am J Health Syst Pharm. 2008 Dec 15;65(24):2347-57. doi: 10.2146/ajhp080155.
4
Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?
Clin Pharmacokinet. 2008;47(1):1-6. doi: 10.2165/00003088-200847010-00001.
5
Thoracic complications of nasogastric tube: review of safe practice.
Interact Cardiovasc Thorac Surg. 2005 Oct;4(5):429-33. doi: 10.1510/icvts.2005.109488. Epub 2005 Jun 21.
7
Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
Aliment Pharmacol Ther. 2005 Dec;22 Suppl 3:25-30. doi: 10.1111/j.1365-2036.2005.02709.x.
8
Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
Int J Pharm. 2005 Aug 11;299(1-2):65-72. doi: 10.1016/j.ijpharm.2005.04.034.
9
Efficacy of esomeprazole in patients with acid-peptic disorders.
Gastroenterol Nurs. 2004 Mar-Apr;27(2):44-9. doi: 10.1097/00001610-200403000-00002.
10
Pharmacologic properties of proton pump inhibitors.
Pharmacotherapy. 2003 Oct;23(10 Pt 2):74S-80S. doi: 10.1592/phco.23.13.74s.31929.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验